idiopathic pulmonary fibrosis

News

Roche increases IPF presence with $1.39bn Promedior buy

Roche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for the deadly lung-scarring disease idiopathic pulmonary fibrosis (IPF) in a deal wort

News

AZ researches kidney and lung drugs with BenevolentAI

AstraZeneca has become the latest big pharma to jump on the artificial intelligence R&D bandwagon, penning a deal with the UK’s BenevolentAI to find new kidney and lung drugs.<

News

Boehringer to develop fibrosis treatment with Inventiva

Boehringer to progress R&D partnership that began last year

News

Galapagos and FibroGen drugs offer hope in IPF

Drugs improve on existing medicines from Boehringer and Roche.

News

Merck to buy Afferent in potential $1.25 bn deal

Merck to develop cough drug.

Views & Analysis

Patient perspective: living with rare lung disease IPF

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition.

Roche increases IPF presence with $1.39bn Promedior buy

AZ researches kidney and lung drugs with BenevolentAI

Boehringer to develop fibrosis treatment with Inventiva

Galapagos and FibroGen drugs offer hope in IPF

Merck to buy Afferent in potential $1.25 bn deal

Patient perspective: living with rare lung disease IPF

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

idiopathic pulmonary fibrosis

Editor's Picks